INFORMACIONES PSIQUIÁTRICAS 251

60 Informaciones Psiquiátricas 2023 - n.º 251 7. Barcella C, Polcwiartek C, Mohr GH, Hodg- es G, Søndergaard K, Niels Bang C, et al. Severe mental illness is associated with increased mortality and severe course of COVID‐19. Acta Psychiatrica Scandinavi- ca.2021; 144(1):82-91 8. Maripuu M, Bendix M, Öhlund L, Wider- ström M, Werneke U. Death Associated With Coronavirus (COVID-19) Infection in Individuals With Severe Mental Disorders in Sweden During the Early Months of the Outbreak—An Exploratory Cross-Sec- tional Analysis of a Population-Based Register Study. Frontiers in psychiatry. 2021; 11: 1538 9. Li L, Li F, Fortunati F, Krystal JH. Asso- ciation of a prior psychiatric diagnosis with mortality among hospitalized pa- tients with Coronavirus disease 2019 (COVID-19) Infection. JAMA network open. 2020; 3(9) 10. Nemani K, Li C, Olfson M, Blessing EM, Razavian N, Chen J, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA psychiatry. 2021; 78(4): 380-386. 11. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: ret- rospective cohort studies of 62 354 COVID-19 cases in the USA. The Lancet Psychiatry. 2021; 8(2): 130-140. 12. Wang Q, Xu R, Volkow ND. Increased risk of COVID‐19 infection and mortal- ity in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021; 20(1): 124-130. 13. Canal-Rivero M, Barragán RC, García AR, Torres NG, Crespo-Facorro B, Ruiz-Veguilla M, et al. Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospec- tive epidemiological study in a represen- tative Spanish population. Schizophrenia research. 2021; 229: 53-54. 14. Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG, Hensley LE, et al. Mid- dle East respiratory syndrome and severe acute respiratory syndrome: current ther- apeutic options and potential targets for novel therapies. Drugs. 2017; 77(18): 1935-1966. 15. Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Na- ture. 2020; 586(7827): 113-119. 16. Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, et al. Broad an- ti-coronavirus activity of Food and Drug Administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. Journal of virology. 2020; 94(21) 17. Bitan DT, Krieger I, Kridin K, Komantscher D, Scheinman Y, Weinstein O, et al. COVID-19 Prevalence and Mortality Among Schizophrenia Patients: A Large- Scale Retrospective Cohort Study. Schizo- phrenia bulletin.2021;47(5):1211–1217 18. Kozloff N, Mulsant BH, Stergiopou- los V, Voineskos AN. The COVID-19 global pandemic: implications for people with schizophrenia and relat- ed disorders. Schizophrenia Bulletin. 2020; 46(4): 752-757. Carlos Rebolleda Gil / Paola Fernández Catalina / Cristina Otero Vicario / Maria González Blanco / Sonia González Vázquez / Jose Luís Arroyo Cifuentes